Researchers at TREAT U are working to develop novel therapeutic agents to specifically target the tumor microenvironment. These agents are nanotechnology-based platforms for the specific delivery of drugs (either small drugs or siRNA). PEGASEMP™, the first developed platform, is specific to two targets in the tumor microenvironment (cancer cells and tumor blood vessels), with triggered release of the transported payload in the intracellular compartment.
To translate scientific discoveries from the lab bench to the clinic, TREATÂ U is following the Medicine Value Chain, performing proof-of-concept pre-clinical trials (in vitro and in vivo studies) and clinical trials (small scale studies in humans to assess safety and effectiveness) to help find and advance the most promising delivery systems for treating oncology patients.
